![](https://cdn.sanity.io/images/0vv8moc6/dermatologytimes/24796cfbd9101eaf4e3fcc8a6e99c8f4103e802b-245x343.jpg?fit=crop&auto=format)
Hematologic Safety of Ruxolitinib Cream in Children with Atopic Dermatitis
New findings from the TRuE-AD3 phase 3 study (NCT04921969) highlight the hematologic laboratory safety results of twice-daily application of 1.5% ruxolitinib cream (Opzelura; Incyte) in children aged 2-11 years with mild to moderate atopic dermatitis (AD). …